Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

340B Purchases To Hit 8% Of Outpatient Brand Drug Sales In 2019 – White Paper

This article was originally published in The Pink Sheet Daily

Executive Summary

Berkeley Research Group finds fault with the oft-cited idea that 340B accounts for only 2% of total drug sales. Meanwhile, 340B hospitals issue their own data showing they serve lower-income populations than other hospitals.


Related Content

Hospital Drug Discount Transparency Bill Faces Heavy ‘Lift’ In Congress
Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill
340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs